



PledPharma

Press Release
12 September 2014

Information video about PLIANT study available

A shortened version of an information video for the PLIANT study that previously has been distributed to all participating clinics in the study is now published on PledPharma's website.

PledPharma has interviewed three doctors involved in the ongoing colorectal cancer study PLIANT. The three oncologists Professor Bengt Glimelius, Professor Per Pfeiffer and Dr. Jitendra Gandhi share their experiences of the study and give their views on why this study is interesting and important.

Watch video here: <http://pledpharma.se/project-pipeline/pp-095-en/?lang=en>

For further information, please contact:

Jacques Näsström, CEO
+46 737 13 09 79
Jacques.nasstrom@pledpharma.se

Michaela Gertz, CFO
+46 709 26 17 75
Michaela.gertz@pledpharma.se

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new therapies for the treatment of life threatening diseases. The initial objective is to develop a drug, PledOx[®], which reduces severe side-effects associated with chemotherapy. The current market for supportive cancer care is some USD 10 billion. PledPharma also evaluates an existing medicines possibility to reduce the damage that occurs on the heart muscle when patients suffer from acute myocardial infarction. In addition to these projects, the company is also evaluating opportunities of using our technology platform in additional areas where there is a significant unmet medical need. PledPharma has the potential to offer patients valuable and unique treatments for serious life-threatening diseases where there is an opportunity fast registration in the US through "breakthrough therapy" designation. This means that the company has the potential to offer shareholders a good return on their investment. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se